Expressions of EphA10 and Gli3 are associated with the clinicopathological characteristics (CPC) of invasive BC
| CPC | Case number | EphA10 | Gli3 | ||||
| Positive number (%) | χ2 | P value | Positive number (%) | χ2 | P value | ||
| Age (years) | |||||||
| ≤45 | 68 | 43 (63.2) | 0.24 | 0.624 | 43 (63.2) | 3.515 | 0.061 |
| >45 | 56 | 33 (58.9) | 26 (46.4) | ||||
| Menopausal status | |||||||
| Premenopausal | 71 | 46 (64.8) | 0.857 | 0.355 | 45 (63.4) | 4.027 | 0.045 |
| Postmenopausal | 53 | 30 (56.6) | 24 (45.3) | ||||
| Histologic grades | |||||||
| Ⅰ | 17 | 7 (41.2) | 12.512 | 0.002 | 6 (35.6) | 15.254 | 0.000 |
| Ⅱ | 49 | 24 (48.9) | 20 (40.8) | ||||
| Ⅲ | 58 | 45 (77.6) | 43 (74.5) | ||||
| Tumor size | |||||||
| ≤3 cm | 57 | 30 (52.6) | 3.334 | 0.068 | 27 (47.4) | 2.928 | 0.087 |
| >3 cm | 67 | 46 (68.7) | 42 (62.7) | ||||
| ER | |||||||
| + | 59 | 30 (50.8) | 5.174 | 0.023 | 29 (49.2) | 1.922 | 0.166 |
| – | 65 | 46 (70.8) | 40 (61.5) | ||||
| PR | |||||||
| + | 64 | 38 (59.4) | 0.205 | 0.651 | 37 (57.8) | 0.252 | 0.616 |
| – | 60 | 38 (63.3) | 32 (53.3) | ||||
| CerB2 | |||||||
| + | 78 | 48 (61.5) | 0.005 | 0.941 | 44 (56.4) | 0.05 | 0.823 |
| – | 46 | 28 (60.9) | 25 (54.3) | ||||
| Lymph node metastasis | |||||||
| No | 56 | 27 (48.2) | 7.359 | 0.008 | 25 (44.6) | 5.008 | 0.025 |
| Yes | 68 | 49 (72.1) | 44 (64.7) | ||||
| TNM stage | |||||||
| Ⅰ+Ⅱ | 66 | 30 (45.5) | 14.914 | 0.000 | 23 (34.9) | 24.726 | 0.000 |
| Ⅲ+Ⅳ | 58 | 46 (79.3) | 46 (79.3) | ||||
BC, breast cancer; ER, estrogen receptor; PR, progesterone receptor; TNM, tumor, node, metastasis.